The GLIDE-C digital therapeutic program integrating CGM with personalized lifestyle coaching reduces HbA1c in adults with mildly uncontrolled type 2 diabetes.
In a prospective observational cohort study of 18 adults with T2DM (baseline HbA1c 7.5%-9.5%), the GLIDE-C app-based intervention combining CGM with diet, exercise, and cognitive behavioral therapy led to a mean HbA1c reduction of 0.59% (P=.05) over 60 days. Postprandial glucose decreased by 25.42 mg/dL (P=.06), and time in range increased by 9.98%, with improvements in sleep quality (P=.04).
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
The GLIDE-C digital therapeutic program integrating CGM with personalized lifestyle coaching reduces HbA1c in adults with mildly uncontrolled type 2 diabetes. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
The GLIDE-C digital therapeutic program integrating CGM with personalized lifestyle coaching reduces HbA1c in adults with mildly uncontrolled type 2 diabetes.
This conclusion is most relevant to: Adults aged ≥18 years with confirmed type 2 diabetes mellitus and baseline HbA1c between 7.5% and 9.5% (mean age 49.45 years, 61.1% male)..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study. (JMIR diabetes, 2026) —
How It Works
The proposed biological pathway:
- ▸Continuous glucose monitoring provides real-time glucose data
- ▸Personalized diet and exercise plans are adjusted based on CGM data
- ▸Cognitive behavioral therapy and coaching support behavior change
- ▸Result: Improved glycemic control and quality of life
Who Might Benefit
Evidence fit by population:
- ▸Adults aged ≥18 years with confirmed type 2 diabetes mellitus and baseline HbA1c between 7.5% and 9.5% (mean age 49.45 years, 61.1% male).
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Small sample size (n=18) limits generalizability
- ▸Short intervention duration (60 days) may not capture long-term effects
- ▸Observational design without a control group precludes causal inference
Frequently Asked Questions
What is the GLIDE-C program?▼
GLIDE-C stands for Glycemic Lifestyle Intervention in Diabetes Empowerment-CGM, an app-based digital therapeutic that integrates continuous glucose monitoring with personalized nutrition, exercise, and cognitive behavioral therapy coaching.
How much did HbA1c decrease in the study?▼
Mean HbA1c decreased by 0.59% from baseline, which was statistically significant (P=.05).
Who was eligible for this study?▼
Adults aged 18 years or older with confirmed type 2 diabetes and baseline HbA1c between 7.5% and 9.5% were included.
What were the main limitations of this research?▼
The study had a small sample size of 18 participants, a short 60-day follow-up, and lacked a control group, making it difficult to attribute improvements solely to the intervention.
References
- 1.Saboo B, Sabharwal M, Gharia M, Aswal D, Modi P, Maheshwari T, Parikh J, Saanyal S, Agrawal J. “App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study..” JMIR diabetes, 2026. PMID: 42418692 DOI: 10.2196/86651